CHAPEL HILL – Altis Biosystems, a Chapel Hill-based biotech research tools company, has raised just north of $3.1 million from a total of 42 investors.
According to an SEC firm, Altis previously had raised $934,592 from seven investors.
“We consider our platforms to be the next generation in compound screening,” says Michael Biron, CEO and co-founder of the company.
The firm is currently developing a stem cell co-culture cassette for advanced compound screening to make drug discovery faster and cheaper. The project is sponsored by the National Institutes of Health, Department of Health and Human Services.
